Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial

Journal of Human Reproductive Sciences

Volumn 9, Issue 3, 2016, Pages 164-172

  Krishna, Deepika ^a   Dhoble, Snehal ^a   Praneesh, Gautham ^a   Rathore, Suvarna ^a   Upadhaya, Amit ^a   Rao, Kamini ^a  

^a Department of Reproductive Medicine Milann the Fertility Center   (India)

Author keywords

Antagonist; gonadotropin releasing hormone agonist trigger; human chorionic gonadotropin trigger; ovarian hyperstimulation syndrome; polycystic ovary syndrome

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADOTROPIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; MUELLERIAN INHIBITING FACTOR; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; TRIPTORELIN;

ADULT; ARTICLE; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CRYOPRESERVATION; EMBRYO DEVELOPMENT; EMBRYO SEGMENTATION; FEMALE; FERTILIZATION; HUMAN; IN VITRO FERTILIZATION; INCIDENCE; MAJOR CLINICAL STUDY; OOCYTE MATURATION; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PRIMARY PREVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TERTIARY CARE CENTER;

EID: 84994065598     PISSN: 09741208     EISSN: 19984766     Source Type: Journal    
DOI: 10.4103/0974-1208.192056     Document Type: Article

References (62)

1. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: Guidance for the clinician. Fertil Steril 2010;94:389-400.
2. Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: Two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013;28:2511-21.
3. Yen SS, Llerena O, Little B, Pearson OH. Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man. J Clin Endocrinol Metab 1968;28:1763-7.
4. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;85:112-20.
5. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update 2003;9:77-96.
6. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Hum Reprod Update 2002;8:559-77.
7. Nastri CO, Teixeira DM, Moroni RM, Leitão VM, Martins WP. Ovarian hyperstimulation syndrome: Pathophysiology, staging, prediction and prevention. Ultrasound Obstet Gynecol 2015;45:377-93.
8. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment. Fertil Steril 1992;58:249-61.
9. Damewood MD, Shen W, Zacur HA, Schlaff WD, Rock JA, Wallach EE. Disappearance of exogenously administered human chorionic gonadotropin. Fertil Steril 1989;52:398-400.
10. Fauser BC, de Jong D, Olivennes F, Wramsby H, Tay C, Itskovitz-Eldor J, et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002;87:709-15.
11. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: A prospective randomized study. Hum Reprod 2005;20:1213-20.
12. Humaidan P, Kol S, Papanikolaou EG; Copenhagen GnRH Agonist Triggering Workshop Group. GnRH agonist for triggering of final oocyte maturation: Time for a change of practice? Hum Reprod Update 2011;17:510-24.
13. Engmann L, DiLuigi A, Schmidt D, Benadiva C, Maier D, Nulsen J. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: A prospective randomized study. Fertil Steril 2008;89:554-61.
14. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004;81:1-5.
15. Humaidan P, Alsbjerg B. GnRHa trigger for final oocyte maturation: Is HCG trigger history? Reprod Biomed Online 2014;29:274-80.
16. Griesinger G, Schultz L, Bauer T, Broessner A, Frambach T, Kissler S. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a «freeze-all» strategy: A prospective multicentric study. Fertil Steril 2011;95:2029-33.
17. Tan BK, Mathur R. Management of ovarian hyperstimulation syndrome. Produced on behalf of the BFS Policy and Practice Committee. Hum Fertil (Camb) 2013;16:151-9.
18. Mocanu E, Redmond ML, Hennelly B, Collins C, Harrison R. Odds of ovarian hyperstimulation syndrome (OHSS)-time for reassessment. Hum Fertil (Camb) 2007;10:175-81.
19. Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV Jr. Early and late presentation of the ovarian hyperstimulation syndrome: Two distinct entities with different risk factors. Hum Reprod 1994;9:792-9.
20. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73:901-7.
21. Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohí J, Simón C. The pathogenesis of ovarian hyperstimulation syndrome: In vivo studies investigating the role of interleukin-1 beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril 1999;71:482-9.
22. Neulen J, Yan Z, Raczek S, Weindel K, Keck C, Weich HA, et al. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: Importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 1995;80:1967-71.
23. Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr Rev 2002;23:141-74.
24. Al-Inany HG, Aboulghar M, Mansour R, Proctor M. Recombinant versus urinary human chorionic gonadotrophin for ovulation induction in assisted conception. Cochrane Database Syst Rev 2005;2:CD003719.
25. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: From theory to practice. Hum Reprod Update 2014;20:124-40.
26. Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): The need for individualized not standardized treatment. Reprod Biol Endocrinol 2012;10:32.
27. Hamilton-Fairley D, Kiddy D, Watson H, Sagle M, Franks S. Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum Reprod 1991;6:1095-9.
28. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006;3:CD001750.
29. Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization. Fertil Steril 2004;82:841-6.
30. Kashyap S, Parker K, Cedars MI, Rosenwaks Z. Ovarian hyperstimulation syndrome prevention strategies: Reducing the human chorionic gonadotropin trigger dose. Semin Reprod Med 2010;28:475-85.
31. Emperaire JC, Edwards RG. Time to revolutionize the triggering of ovulation. Reprod Biomed Online 2004;9:480-3.
32. Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Macedo CR. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2014;11:CD006105.
33. Garcia-Velasco JA, Isaza VA, Quea G, Pellicer A. Coasting for the prevention of ovarian hyperstimulation syndrome: Much ado about nothing? Fertil Steril 2006;85:547-54.
34. D'Angelo A, Brown J, Amso NN. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011;2:CD002811.
35. DiLuigi AJ, Engmann L, Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting. Fertil Steril 2010;94:1111-4.
36. Queenan JT Jr., Veeck LL, Toner JP, Oehninger S, Muasher SJ. Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. Hum Reprod 1997;12:1573-6.
37. van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2011;10:CD009154.
38. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: A current survey. Fertil Steril 1978;30:255-68.
39. Youssef MA, Al-Inany HG, Evers JL, Aboulghar M. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011;2:CD001302.
40. Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2012;2:CD008605.
41. Leitao VM, Moroni RM, Seko LM, Nastri CO, Martins WP. Cabergoline for the prevention of ovarian hyperstimulation syndrome: Systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2014;101:664-75.
42. Cenksoy C, Cenksoy PO, Erdem O, Sancak B, Gursoy R. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model. Eur J Obstet Gynecol Reprod Biol 2014;174:86-90.
43. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309-15.
44. Itskovitz J, Boldes R, Barlev A, Erlik Y, Kahana L, Brandes JM. The induction of LH surge and oocyte maturation by GnRH analogue (Buserelin) in women undergoing ovarian stimulation for in vitro fertilization. Gynecol Endocrinol 1988;2 Suppl 1:165.
45. Humaidan P, Papanikolaou EG, Tarlatzis BC. GnRHa to trigger final oocyte maturation: A time to reconsider. Hum Reprod 2009;24:2389-94.
46. Devroey P, Polyzos NP, Blockeel C. An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod 2011;26:2593-7.
47. Youssef MA, Van der Veen F, AlInany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, et al. Gonadotropinreleasing hormone agonist versus HCG for oocyte triggering in antagonistassisted reproductive technology. Cochrane Database Syst Rev 2014;10:CD008046.
48. Balaban B, Urman B, Ata B, Isiklar A, Larman MG, Hamilton R, et al. A randomised controlled study of human day 3 embryo cryopreservation by slow freezing or vitrification: Vitrification is associated with higher survival, metabolism and blastocyst formation. Hum Reprod 2008;23:1976-82.
49. Maheshwari A, Pandey S, Shetty A, Hamilton M, Bhattacharya S. Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: A systematic review and meta-analysis. Fertil Steril 2012;98:368-77.
50. Fatemi HM, Popovic-Todorovic B. Implantation in assisted reproduction: A look at endometrial receptivity. Reprod Biomed Online 2013;27:530-8.
51. Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: A prospective randomized trial. Hum Reprod 2006;21:1260-5.
52. Griesinger G, von Otte S, Schroer A, Ludwig AK, Diedrich K, Al-Hasani S, et al. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: A prospective, observational proof-of-concept study. Hum Reprod 2007;22:1348-52.
53. Manzanares MA, Gómez-Palomares JL, Ricciarelli E, Hernández ER. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertil Steril 2010;93:1215-9.
54. Youssef MA, Abdelmoty HI, Ahmed MA, Elmohamady M. GnRH agonist for final oocyte maturation in GnRH antagonist co-treated IVF/ICSI treatment cycles: Systematic review and meta-analysis. J Adv Res 2015;6:341-9.
55. Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: A randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online 2009;19:486-92.
56. Sismanoglu A, Tekin HI, Erden HF, Ciray NH, Ulug U, Bahceci M. Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: A prospective randomized cross-over trial. J Assist Reprod Genet 2009;26:251-6.
57. Hernández ER, Gómez-Palomares JL, Ricciarelli E. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles. Fertil Steril 2009;91 4 Suppl: 1358-61.
58. Cerrillo M, Rodríguez S, Mayoral M, Pacheco A, Martínez-Salazar J, Garcia-Velasco JA. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: A rationale for OHSS reduction. Fertil Steril 2009;91 4 Suppl: 1526-8.
59. Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013;28:2522-8.
60. Datta AK, Eapen A, Birch H, Kurinchi-Selvan A, Lockwood G. Retrospective comparison of GnRH agonist trigger with HCG trigger in GnRH antagonist cycles in anticipated high-responders. Reprod Biomed Online 2014;29:552-8.
61. Fatemi HM, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and «freeze-all» approach in GnRH antagonist protocol. Fertil Steril 2014;101:1008-11.
62. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: A systematic review and meta-analysis. Hum Reprod Update 2006;12:159-68.